6 results
Search Results
2. Lost companions: a new quill mite species and its possible coextinction with the Carolina parakeet.
- Author
-
Skoracki, Maciej, Unsöld, Markus, Patan, Milena, and Sikora, Bozena
- Subjects
- *
BUDGERIGAR , *SPECIES , *PARROTS , *MITES , *BIOLOGICAL extinction , *TWENTIETH century , *ACARIFORMES , *PARASITES - Abstract
Investigations of the parasites associated with extinct avian species provide unique insights into the ecology and evolution of both hosts and their parasitic counterparts. In the present paper, a new quill mite species, Peristerophila conuropsis sp. n., belonging to the family Syringophilidae (Prostigmata: Cheyletoidea) is described from the Carolina parakeet Conuropsis carolinensis Linnaeus (Psittaciformes: Psittacidae). This new species was collected from museum dry skin of the Carolina parakeet, the only native representative of the Psittacidae in the United States, which was an abundant resident of the southeastern and midwestern states and has been extinct in the beginning of the 20th century. Comment on the current taxonomic state and host associations of the genus Peristerophila are provided. Based on the host associations and habitats occupied by Peristerophila and related genera on parrots, it is hypothesized with the high probability that P. conuropsis has been extinct along with its host. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Study: Counterfeits/fentanyl making drug use more deadly for adolescents.
- Author
-
Knopf, Alison
- Subjects
- *
HEALTH policy , *OCCUPATIONAL roles , *SAFETY , *NARCOTICS , *DISEASE clusters , *SUBSTANCE abuse , *DRUG overdose , *SOCIAL media , *FENTANYL , *CURRICULUM , *PARENTING , *HEALTH literacy , *SCHOOLS , *POLICY sciences , *DRUG counterfeiting , *DOSAGE forms of drugs , *PATIENT safety , *ADOLESCENCE - Abstract
As Scott E. Hadland, M.D., senior author of a dramatic paper published last week in the New England Journal of Medicine puts it, drug use among adolescents is not getting more common — it's at its lowest in almost 50 years. But it's getting more deadly, due to fentanyl. In "The Overdose Crisis among U.S. Adolescents," by Hadland and lead author Joseph Friedman, Ph.D., the problem is laid out clearly: After guns and car crashes, overdose (OD) deaths are now the third leading cause of death among adolescents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. RHODIOLA ROSEA.
- Author
-
COX, JEFF
- Subjects
- *
ROSEROOT , *VITAMIN C , *SUCCULENT plants , *MEMORY loss , *PHYSICAL mobility , *SUMATRIPTAN ,WESTERN countries - Abstract
Rhodiola rosea, also known as golden root or roseroot, is a succulent plant that grows in mountainous regions with severe winters. It has a long history of use as a medicinal herb, with records dating back to ancient times. Rhodiola rosea is rich in phenolic compounds and vitamin C, which have healing and protective properties for both humans and animals. Modern research has discovered that it is an adaptogen, increasing resistance to stress and improving physical and mental performance. It is also a source of antioxidants and has potential benefits for pain relief, headache, and memory loss. Rhodiola rosea can be grown in various regions, including the United States, and its seeds are readily available online. However, it is not well-known in the Western world due to most scientific papers being published in Slavic or Scandinavian languages. [Extracted from the article]
- Published
- 2024
5. The American Academy of Child and Adolescent Psychiatry seeks submissions for the 2024 Annual Meeting.
- Subjects
- *
MEETINGS , *PSYCHIATRY , *CONFERENCES & conventions , *CHILD psychiatry , *ADOLESCENT psychiatry , *INFORMATION resources , *PROFESSIONAL associations - Abstract
The American Academy of Child and Adolescent Psychiatry's (AACAP's) Program Committee has issued a Call for Papers for submission of abstracts of original investigations for consideration in the 2024 Annual Meeting of AACAP, October 14‐19, in Seattle. AACAP is planning for an in‐person meeting in Seattle and as such, will require all presenters to be in‐person in Seattle for their presentation. The Call for Papers deadline is Feb. 15, 2024 (11:59 p.m. EST). For more information, visit https://aacap.confex.com/aacap/2024/cfp.cgi. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. NIDA on dramatic increase of mushroom seizures.
- Author
-
Knopf, Alison
- Subjects
- *
MUSHROOMS , *SUBSTANCE abuse , *ALKALOIDS , *HALLUCINOGENIC drugs , *SOCIAL control - Abstract
From 2017 – 2022, law enforcement seizures across the United States of mushrooms containing psilocybin increased dramatically, according to a new study funded by the National Institute on Drug Abuse (NIDA). The number of law enforcement seizures increased from 402 seizures in 2017 to 1,396 in 2022. In addition, the total weight of psilocybin mushrooms seized by law enforcement increased from 226 kg (498 lbs.) seized in 2017 compared with 844 kg (1,861 lbs.) in 2022. This analysis, published in Drug and Alcohol Dependence, was led by researchers at New York University (NYU) Langone Health in New York City, and the University of Florida, Gainesville. The data used for the analysis were collected through the High Intensity Drug Trafficking Areas (HIDTA) program, a grant program aimed at reducing drug trafficking and misuse administered by the Office of National Drug Control Policy. Though law enforcement seizures do not necessarily reflect prevalence of use, they represent an indicator of the availability of illicit drugs. "We are in the middle of a rapidly evolving cultural, media, and legal landscape when it comes to psychedelics, and we need data to help shape informed and appropriate public health strategies," said NIDA Director Nora D. Volkow, M.D., in announcing the research publication last week. "Moving forward, we must continue to track data on the availability of psychedelics, patterns in use, and associated health effects to guide efforts in promoting accurate education and reducing potential harms among people who do plan to use psychedelic drugs." Adverse effects of psilocybin mushrooms, such as "bad trips," are marked by "distorted thinking, perceptual changes, putting oneself in physical danger, and intense feelings of fear, anxiety, and confusion," according to NIDA. "People who take psychedelic drugs like psilocybin may also experience short‐term side effects such as raised blood pressure and heart rate, agitation, confusion, vomiting, or nausea, which may be severe and require medical attention." Joseph J. Palamar, Ph.D., M.P.H., associate professor at the NYU Grossman School of Medicine, co‐investigator on the NIDA‐funded National Drug Early Warning System (NDEWS), and lead author on the paper, said "Research studies suggesting its effectiveness in treating mental health issues and extensive positive media coverage may lead some people to seek 'shrooms' outside of medical contexts. People who use psilocybin outside of medical supervision need to be educated about risks associated with use." [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.